Opthalmics Partnering Terms & Agreements

Published: January 2013
No. of Pages: 605
   

This report provides a detailed understanding and analysis of how and why companies enter opthalmics partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest opthalmics deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of opthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in opthalmics dealmaking since 2007covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading opthalmics deals since 2007. Deals are listed by headline value, signed by bigpharma and bigbiotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapters 4 and 5 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of opthalmics deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides comprehensive access to all opthalmics deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive directory of all opthalmics partnering deals by specific therapeutic target announced since 2007. The chapter is organized by specific opthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all opthalmics partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in opthalmics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of opthalmics technologies and products.

Key benefits

Opthalmics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of opthalmics deal trends since 2007
  • Access opthalmics deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between opthalmics partner companies
  • Comprehensive access to over 1500 links to actual opthalmics deals entered into by the world’s biopharma companies
  • Indepth review of dental deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner opthalmics opportunities
  • Uncover companies actively partnering opthalmics opportunities

Report scope

Opthalmics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to opthalmics trends and structure of deals entered into by leading companies worldwide.

OpthalmicsPartnering Terms and Agreements includes:

  • Trends in opthalmics dealmaking in the biopharma industry since 2007
  • Analysis of opthalmics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of opthalmics deal contract documents
  • Comprehensive access to over 350 opthalmics deal records
  • The leading opthalmics deals by value since 2007
  • Most active opthalmics dealmakers since 2007

In Opthalmics Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value o Upfront payment value
  • Royalty rate value o Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Opthalmics Partnering Terms & Agreements

Table of Contents   

Executive Summary

Chapter 1 – Introduction       

Chapter 2 – Trends in opthalmics dealmaking          
2.1. Introduction          
2.2. Opthalmics partnering over the years        
2.3. Bigpharma opthalmics dealmaking activity
2.4. Opthalmics partnering by deal type
2.5. Opthalmics partnering by industry sector  
2.6. Opthalmics partnering by stage of development    
2.7. Opthalmics partnering by technology type
2.9. Opthalmics partnering by therapeutic indication     
2.10. Average deal terms for Opthalmology     
2.10.1 Opthalmics headline values       
2.10.2 Opthalmics upfront payments    
2.10.3 Opthalmics milestone payments
2.10.4 Opthalmics royalty rates

Chapter 3 – Leading opthalmics deals          
3.1. Introduction          
3.2. Top opthalmics deals by value      

Chapter 4 – Bigpharma opthalmics deals
4.1. Introduction          
4.2. How to use bigpharma partnering deals     
4.3. Bigpharma opthalmics partnering company profiles
Allergan          
AstraZeneca   
Bayer 
Biogen Idec    
Boehringer Ingelheim  
Dainippon Sumitomo   
Eli Lilly
Gilead Sciences          
GlaxoSmithKline         
Johnson & Johnson     
Merck & Co    
Novartis         
Otsuka
Pfizer 
Roche
Sanofi 
Servier
Takeda
Teva  
Valeant

Chapter 5 – Opthalmics partnering contracts directory        
5.1. Introduction          
5.2. Company A-Z       
5.3. By deal type         
Asset purchase
Assignment    
Bigpharma outlicensing
Co-development          
Collaborative R&D      
Co-market      
Contract service         
Co-promotion  
Development  
Distribution     
Equity purchase          
Grant  
Joint venture   
Licensing        
Litigation        
Manufacturing 
Marketing       
Option
Promotion       
Research        
Settlement      
Sub-license    
Supply
Termination    
Warranty        
5.4. By stage of development  
Discovery       
Marketed        
Formulation    
Phase I
Phase II          
Phase III         
Preclinical      
Regulatory      
5.5. By technology type
Analysis         
Assays
Biological compounds 
Cell culture     
Cell therapy    
Clinical testing
Devices          
Diagnostics    
Discovery tools
Drug delivery  
Enabling technology    
Equipment      
Facilities         
Gene therapy  
Genomics       
Implant
Industrial chemicals    
In vitro models
Oligonucleotide
Orphan drug   
Peptides         
Processes      
Proteomics     
Radio/Chemo-therapy 
Recombinant DNA      
Research services      
Research supplies      
RNA therapeutics        
Screening       
Small molecules         
Stem cells      
Toxicity

Chapter 6 – Opthalmics dealmaking by therapeutic target   
6.1. Introduction          
6.2. Deals by therapeutic target
Breast
Cardiovascular
Central Nervous System         
Dental
Dermatology   
Gastrointestinal
Genetic disorders       
Genitourinary  
Gynaecology  
Hematology    
Hospital care  
Immunology    
Infectives       
Metabolic        
Musculoskeletal          
Oncology        
Ophthalmics   
Pediatrics       
Respiratory

Appendices   
Appendix 1 – Directory of opthalmics deals by company A-Z 2007-2012
Appendix 2 – Directory of opthalmics deals by deal type 2007-2012      
Appendix 3 – Directory of opthalmics deals by stage of development 2007-2012
Appendix 4 – Directory of opthalmics deals by technology type 2007-2012        
Appendix 5 – Partnering resource center 

Online partnering        
Partnering events       
Further reading on dealmaking
Deal type definitions    
About Wildwood Ventures        
Current Partnering      
Current Agreements    
Current Reports          
Recent titles from CurrentPartnering    
Order Form – Reports

List of Figures

Figure 1: Opthalmics partnering since 2007     
Figure 2: Bigpharma – top 50 – Opthalmics deals 2007 to 2012
Figure 3: Bigpharma opthalmics deal frequency – 2007 to 2012
Figure 4: Opthalmics partnering by deal type since 2007          
Figure 5: Opthalmics partnering by industry sector since 2007 
Figure 6: Opthalmics partnering by stage of development since 2007   
Figure 7: Opthalmics partnering by technology type since 2007
Figure 8: Opthalmics partnering by opthalmology target since 2007      
Figure 9: Opthalmics deals with a headline value         
Figure 10: Opthalmics deal headline value distribution, US$million – discovery stage    
Figure 11: Opthalmics deal headline value distribution, US$million – preclinical stage   
Figure 12: Opthalmics deal headline value distribution, US$million – phase I stage        
Figure 13: Opthalmics deal headline value distribution, US$million – phase II stage       
Figure 14: Opthalmics deal headline value distribution, US$million – phase III stage      
Figure 15: Opthalmics deal headline value distribution, US$million – regulatory stage   
Figure 16: Opthalmics deal headline value distribution, US$million – marketed stage     
Figure 17: Summary median headline value by stage of development, 2007-2012          
Figure 18 Opthalmics deals with upfront payment values          
Figure 19: Opthalmics deal upfront payment distribution, US$million – discovery stage 
Figure 20: Opthalmics deal upfront payment distribution, US$million – preclinical stage 
Figure 21: Opthalmics deal upfront payment distribution, US$million – phase I stage     
Figure 22: Opthalmics deal upfront payment distribution, US$million – phase II stage    
Figure 23: Opthalmics deal upfront payment distribution, US$million – phase III stage   
Figure 24: Opthalmics deal upfront payment distribution, US$million – regulatory stage 
Figure 25: Opthalmics deal upfront payment distribution, US$million – marketed stage  
Figure 26: Summary median upfront payments by stage of development, 2007-2012     
Figure 27: Opthalmics deals with milestone payments  
Figure 28: Opthalmics deal milestone distribution, US$million – discovery stage
Figure 29: Opthalmics deal milestone distribution, US$million – preclinical stage
Figure 30: Opthalmics deal milestone distribution, US$million – phase I stage   
Figure 31: Opthalmics deal milestone distribution, US$million – phase II stage  
Figure 32: Opthalmics deal milestone distribution, US$million – phase III stage 
Figure 33: Opthalmics deal milestone distribution, US$million – regulatory stage
Figure 34: Opthalmics deal milestone distribution, US$million – marketed stage
Figure 35: Opthalmics deals with royalty rates, %        
Figure 36: Opthalmics deal royalty rate distribution, US$million – discovery stage        
Figure 37: Opthalmics deal royalty rate distribution, US$million – preclinical stage        
Figure 38: Opthalmics deal royalty rate distribution, US$million – phase I stage
Figure 39: Opthalmics deal royalty rate distribution, US$million – phase II stage
Figure 40: Opthalmics deal royalty rate distribution, US$million – phase III stage          
Figure 41: Opthalmics deal royalty rate distribution, US$million – regulatory stage        
Figure 42: Summary median royalty rate by stage of development, 2007-2012  
Figure 43: Top opthalmics deals by value since 2007   
Figure 44: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Breast)      
Figure 45: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Cardiovascular)     
Figure 46: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Central nervous system)    
Figure 47: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Dental)      
Figure 48: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Dermatology)         
Figure 49: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Gastrointestinal)    
Figure 50: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Genetic disorders) 
Figure 51: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Genitourinary)        
Figure 52: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Gynaecology)        
Figure 53: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Hematology)          
Figure 54: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Hospital care)        
Figure 55: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Immunology)         
Figure 56: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Infectives) 
Figure 57: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Metabolic) 
Figure 58: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Musculoskeletal)    
Figure 59: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Oncology) 
Figure 60: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Opthalmics)
Figure 61: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Pediatrics) 
Figure 62: Recent deals (Jan 2007 to Nov 2012) - By therapy area (Respiratory)
Figure 63: Online partnering resources
Figure 64: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering48


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Bioinformatics Partnering Terms and Agreements

    The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.Trend...

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Vaccine Partnering Terms and Agreements

    The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in vaccine a...

  • Drug Delivery Partnering Terms and Agreements

    The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.The report p...

  • Antibody Partnering Terms and Agreements

    The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a ...

  • Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world’s bioph...

  • Biomarker Partnering Terms and Agreements

    The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in bioma...

  • Companion Diagnostics Partnering Terms & Agreements

    The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access tthe companion diagnostics partnering deals and agreements entered intby the worlds leading healthcare companies....

  • Infectives Vaccine Partnering Terms and Agreements

    The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectives vaccine partnering deals. The majority of deals are development stage whereby the licensee obtai...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Medical Devices market as per your needs. Get the best of Medical Devices research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100